Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade

NIAID Data Ecosystem2026-05-02 收录

肝细胞癌免疫治疗

三级淋巴结构病理分析

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272348 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

创建时间：

2024-09-14

HCC Immunotherapy

肝细胞癌免疫治疗

肿瘤耐药机制

We collected additional tumor tissues from the initial resection of two early-stage HCC patients for Stereo-seq. These patients were later put on immunotherapy with atezolizumab + bevacizumab after th

Figshare2023-09-23 更新40

Data_Sheet_1_Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.XLS

肝细胞癌免疫治疗

生物标志物研究

Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that pred

NIAID Data Ecosystem20

Additional file 1 of Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

肝细胞癌免疫治疗

超进展性疾病评估

Additional file 1: Supplementary Fig. 1. Progression-free survival (A) and overall survival (B) of the whole study population. Supplementary Fig. 2. Overall survival according to the CRAFITY scores. S

Figshare2024-08-13 更新10

Clinical efficacy and biomarker analysis of stereotactic body radiotherapy combined with sintilimab and a bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma

肝细胞癌免疫治疗

PD-1

Immune checkpoint inhibitor (ICI) resistance in advanced hepatocellular carcinoma (HCC)poses a major therapeutic challenge. Here, we report a phase 2 trial evaluating stereotactic bodyradiotherapy (SB

NIAID Data Ecosystem40

Supplementary Material for: Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma

肝细胞癌免疫治疗

超进展性疾病

Introduction: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (H

NIAID Data Ecosystem10

Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade

资源简介：

相关数据集